Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Thomas Lenns

Internal Medicine Hilton Head Island, SC Medical Doctor

NPI 1780778555 CMS profile 262561

89 Main St, Hilton Head Island, SC 29926

Open in the dashboard

General payments

$5,447

233 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Thomas Lenns of Hilton Head Island, SC is reported in the CMS Open Payments database as having received $5,447 across 233 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 90th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $399 16
2024 General $381 19
2023 General $417 22
2022 General $778 39
2021 General $730 44
2020 General $673 46
2019 General $2,069 47

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Thomas Lenns
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Thomas Lenns were reported at $399. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Thomas Lenns Internal Medicine median Middle half National median
2019 $2,069 $159 $48–$570 $163
2020 $673 $119 $33–$402 $114
2021 $730 $135 $37–$521 $132
2022 $778 $141 $42–$496 $149
2023 $417 $149 $45–$519 $160
2024 $381 $154 $47–$537 $164
2025 $399 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Abbott Laboratories $1,133 9 payments
  2. Amgen Inc. $564 25 payments
  3. Novartis Pharmaceuticals Corporation $445 24 payments
  4. Janssen Pharmaceuticals, Inc $434 23 payments
  5. Novo Nordisk Inc $393 21 payments
  6. Astellas Pharma US Inc $349 13 payments
  7. GlaxoSmithKline, LLC. $260 13 payments
  8. Pfizer Inc. $180 11 payments
  9. Amarin Pharma Inc. $173 11 payments
  10. E.R. Squibb & Sons, L.L.C. $169 12 payments
  11. Other $1,345 71 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,374 230 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $984 1 payment
  3. Education $89 2 payments
Products named General payments · program years 2019–2025
  1. EVENITY $402 17 payments
  2. RYBELSUS $360 19 payments
  3. XARELTO $314 22 payments
  4. INVOKANA $257 11 payments
  5. MYRBETRIQ $256 11 payments
  6. Ozempic $254 17 payments
  7. TRELEGY ELLIPTA $202 10 payments
  8. Prolia $188 12 payments
  9. ENTRESTO $186 11 payments
  10. ELIQUIS $169 12 payments
  11. Other $2,887 165 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 126 drugs

Part D claims

6,104

Median for Internal Medicine: 777

Drug cost

$771,919

Median for Internal Medicine: $73,373

Branded share of claims

20.7%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 201 $193,959
Mounjaro Tirzepatide Brand 68 $70,134
Myrbetriq Mirabegron Brand 64 $53,868
Jardiance Empagliflozin Brand 36 $50,267
Rybelsus Semaglutide Brand 31 $46,557
Ozempic Semaglutide Brand 48 $45,275
Xarelto Rivaroxaban Brand 37 $36,352
Januvia Sitagliptin Phosphate Brand 38 $32,642
Farxiga Dapagliflozin Propanediol Brand 26 $27,480
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 28 $26,882

The 10 drugs with the highest cost, of 126 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 56 billing codes

Paid by Medicare

$259,683

Of which drugs: $95,283

Medicare patients

392

Average age 79

Services billed

8,930

204 women, 188 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 71%
Arthritis 48%
Atrial fibrillation 26%
Ischemic heart disease 21%
Diabetes 18%
Cancer 16%
COPD 13%
Heart failure 12%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, denosumab, 1 mg J0897 Office 16 1,680 $34,570
Vaccine for influenza for injection into muscle 90662 Office 172 172 $14,073
Pcv20 vaccine im 90677 Office 30 30 $8,698

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 11 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
LEQVIO
  • Novartis Pharmaceuticals Corporation $42
$42 — —
Otezla
  • Amgen Inc. $41
$41 — —
Repatha
  • Amgen Inc. $41
$41 — —
REXULTI
  • Otsuka America Pharmaceutical, Inc. $37
$37 — —
NUZYRA
  • Paratek Pharmaceuticals, Inc. $33
$33 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 11 in the dashboard with a free account

Records

233 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in South Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record